Stockreport

AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

AzurRx BioPharma, Inc.  (AZRX) 
Last azurrx biopharma, inc. earnings: 11/14 04:31 pm Check Earnings Report
PDF IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. (NASDAQ:AZR [Read more]